Cocrystal Pharma, INC Form 4 insider transactions

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., purchased 10,000 shares of common stock on August 5, 2026 for $0.98 per share.

Cocrystal Pharma, Inc. reports the grant of stock options to CEO James Sapirstein under the 2025 Equity Incentive Plan.

Cocrystal Pharma Director Phillip Frost, MD, increased his indirect beneficial ownership by purchasing 20,000 shares of common stock.

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, disclosed a planned acquisition of 50,000 common shares under a Rule 10b5-1 plan.

Cocrystal Pharma Director Roger D. Kornberg received a grant of 24,615 non-qualified stock options with an exercise price of $1.10.

Cocrystal Pharma's Director, Richard C. Pfenniger Jr., was granted 16,410 non-qualified stock options with an exercise price of $1.1 under the 2025 Equity Incentive Plan.

Cocrystal Pharma's President and Co-CEO, Sam Lee, was granted 49,229 non-qualified stock options with an exercise price of $1.1, vesting over time.

Cocrystal Pharma, Inc. director Fred Hassan received a grant of 16,410 non-qualified stock options with an exercise price of $1.10, vesting over time.

Cocrystal Pharma's Co-CEO and CFO, James Joseph Martin, was granted 49,229 non-qualified stock options with an exercise price of $1.1, vesting over time.

Cocrystal Pharma, Inc. granted 24,615 non-qualified stock options to Director Phillip Frost, MD, with an exercise price of $1.10, vesting over a multi-year period.

Cocrystal Pharma, Inc. director Anthony J. Japour was granted 16,410 non-qualified stock options with an exercise price of $1.1.

Cocrystal Pharma director Steven D. Rubin was granted 16,410 non-qualified stock options under the company's 2025 Equity Incentive Plan.

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 50,000 shares of common stock at a weighted average price of $0.9455.

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 20,000 shares of common stock at a weighted average price of $0.9655.

Phillip Frost MD, a Director and 10% owner of Cocrystal Pharma, Inc., has filed a Form 4 detailing planned future purchases of common stock totaling 65,000 shares.

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 4,000 shares of common stock through indirect ownership.

Phillip Frost, a Director and 10% Owner of Cocrystal Pharma, acquired 20,000 shares of common stock at a weighted average price of $0.9406.

Cocrystal Pharma's Director and 10% owner, Phillip Frost MD, acquired 359,713 common shares and 719,426 warrants through an indirect trust.

Cocrystal Pharma Director Fred Hassan acquired 359,713 common shares and 719,426 warrants, increasing his beneficial ownership in the company.

Cocrystal Pharma Director Richard C. Pfenniger Jr. acquired 20,000 shares of common stock and 40,000 warrants.

Cocrystal Pharma's Co-CEO and CFO, James Joseph Martin, acquired 3,598 shares of common stock and 7,196 warrants in a recent transaction.

Director Roger D. Kornberg reports acquisition of restricted stock units in Cocrystal Pharma, Inc.

Phillip Frost reports acquiring 27,100 shares of Cocrystal Pharma stock and disposing of 27,100 shares in a transaction on October 9, 2024, while also detailing indirect ownership through Frost Gamma Investments Trust.

Director Steven Rubin acquired 18,957 shares of Cocrystal Pharma through restricted stock units, increasing his direct holdings.

Sam Lee, President and Co-CEO of Cocrystal Pharma, reports the acquisition and disposal of common stock and restricted stock units.

Director Richard C. Pfenniger Jr. reports acquiring and disposing of Cocrystal Pharma, Inc. common stock and holding restricted stock units.

James Martin, Co-CEO and CFO of Cocrystal Pharma, reports acquiring 40,000 shares of common stock and disposing of 40,569 shares through restricted stock units.

Director Anthony Japour reports acquisition of restricted stock units in Cocrystal Pharma, Inc.

Director Fred Hassan reports acquisition of 8,067 restricted stock units (RSUs) in Cocrystal Pharma, Inc.